The combination treatment was associated with a higher continuous abstinence rate at 12 weeks ( 55.4 % vs 40.9 % ; odds ratio [ OR ] , 1.85 ; 95 % CI , 1.19-2 .89 ; P = .007 ) and 24 weeks ( 49.0 % vs 32.6 % ; OR , 1.98 ; 95 % CI , 1.25-3 .14 ; P = .004 ) and point prevalence abstinence rate at 6 months ( 65.1 % vs 46.7 % ; OR , 2.13 ; 95 % CI , 1.32-3 .43 ; P = .002 ) .